Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Telitacicept in Myasthenia gravis. The expected timing is based on the latest available company guidance and may change.
10/29/25– Reported sustained 48wk efficacy & safety data at AANEM'25. 11/13/25- Study ongoing. 03/30/26:- Enrollment ongoing in UPSTREAM MG Phase 3 trial; topline data expected in H1 2027. 05/13/26:- UPSTREAM MG Ph3 enrollment ongoing; topline data still anticipated in H1 2027. 08/11/26:- UPSTREAM MG enrollment ongoing; topline data still anticipated in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.